Liaoning Chengda Biotechnology Co (SHSE:688739) Piotroski F-Score: 6 (As of Jul. 07, 2026) — 20% Above Median


SHSE:688739 Liaoning Chengda Biotechnology Co Ltd SHSE:688739
69 GF Score
Price ¥19.65
GF Value ¥22.14
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Liaoning Chengda Biotechnology Co Piotroski F-Score?

Liaoning Chengda Biotechnology Co SHSE:688739 -3.34% 69 Piotroski F-Score is 6 as of Jul. 07, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates SHSE:688739 with a GF Score™ of 69/100 and a GF Value™ of ¥22.14 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,331 Biotechnology companies, Liaoning Chengda Biotechnology Co ranks better than 91.96% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Liaoning Chengda Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Liaoning Chengda Biotechnology Co's Piotroski F-Score or its related term are showing as below:

SHSE:688739' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Liaoning Chengda Biotechnology Co was 8. The lowest was 3. And the median was 5.

Liaoning Chengda Biotechnology Co  (SHSE:688739) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Liaoning Chengda Biotechnology Co Piotroski F-Score Related Terms


Liaoning Chengda Biotechnology Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Liaoning Chengda Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liaoning Chengda Biotechnology Co Piotroski F-Score Chart

Liaoning Chengda Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 5.00 4.00 6.00

Liaoning Chengda Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 6.00 5.00 6.00 6.00

SHSE:688739 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Liaoning Chengda Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liaoning Chengda Biotechnology Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liaoning Chengda Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Liaoning Chengda Biotechnology Co's Piotroski F-Score falls into.


SHSE:688739
69GF Score
Liaoning Chengda Biotechnology Co Ltd SHSE:688739
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 50.077 + 42.517 + -33.022 + -1.908 = ¥58 Mil.
Cash Flow from Operations was 87.985 + 44.537 + 169.847 + 19.647 = ¥322 Mil.
Revenue was 348.382 + 389.109 + 294.401 + 273.348 = ¥1,305 Mil.
Gross Profit was 287.13 + 313.579 + 230.813 + 202.405 = ¥1,034 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(10080.623 + 9786.556 + 9802.754 + 9746.208 + 9675.551) / 5 = ¥9818.3384 Mil.
Total Assets at the begining of this year (Mar25) was ¥10,081 Mil.
Long-Term Debt & Capital Lease Obligation was ¥5 Mil.
Total Current Assets was ¥6,721 Mil.
Total Current Liabilities was ¥236 Mil.
Net Income was 138.75 + 109.485 + 13.123 + 72.218 = ¥334 Mil.

Revenue was 515.984 + 421.997 + 373.552 + 358.396 = ¥1,670 Mil.
Gross Profit was 427.071 + 350.736 + 310.099 + 271.948 = ¥1,360 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(10102.562 + 9931.394 + 10033.331 + 10051.587 + 10080.623) / 5 = ¥10039.8994 Mil.
Total Assets at the begining of last year (Mar24) was ¥10,103 Mil.
Long-Term Debt & Capital Lease Obligation was ¥9 Mil.
Total Current Assets was ¥7,074 Mil.
Total Current Liabilities was ¥353 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Liaoning Chengda Biotechnology Co's current Net Income (TTM) was 58. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Liaoning Chengda Biotechnology Co's current Cash Flow from Operations (TTM) was 322. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=57.664/10080.623
=0.00572028

ROA (Last Year)=Net Income/Total Assets (Mar24)
=333.576/10102.562
=0.03301895

Liaoning Chengda Biotechnology Co's return on assets of this year was 0.00572028. Liaoning Chengda Biotechnology Co's return on assets of last year was 0.03301895. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Liaoning Chengda Biotechnology Co's current Net Income (TTM) was 58. Liaoning Chengda Biotechnology Co's current Cash Flow from Operations (TTM) was 322. ==> 322 > 58 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4.83/9818.3384
=0.00049194

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=9.483/10039.8994
=0.00094453

Liaoning Chengda Biotechnology Co's gearing of this year was 0.00049194. Liaoning Chengda Biotechnology Co's gearing of last year was 0.00094453. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=6721.488/236.495
=28.42126895

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7073.88/353.318
=20.02128394

Liaoning Chengda Biotechnology Co's current ratio of this year was 28.42126895. Liaoning Chengda Biotechnology Co's current ratio of last year was 20.02128394. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Liaoning Chengda Biotechnology Co's number of shares in issue this year was 381.542. Liaoning Chengda Biotechnology Co's number of shares in issue last year was 412.674. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1033.927/1305.24
=0.79213555

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1359.854/1669.929
=0.81431845

Liaoning Chengda Biotechnology Co's gross margin of this year was 0.79213555. Liaoning Chengda Biotechnology Co's gross margin of last year was 0.81431845. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1305.24/10080.623
=0.12948009

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1669.929/10102.562
=0.16529758

Liaoning Chengda Biotechnology Co's asset turnover of this year was 0.12948009. Liaoning Chengda Biotechnology Co's asset turnover of last year was 0.16529758. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Liaoning Chengda Biotechnology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Liaoning Chengda Biotechnology Co (SHSE:688739) has a Piotroski F-Score of 6 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Liaoning Chengda Biotechnology Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Liaoning Chengda Biotechnology Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Liaoning Chengda Biotechnology Co ranks #107 out of 1331 companies in the Biotechnology industry, placing it in the top 8%.
Is Liaoning Chengda Biotechnology Co's Piotroski F-Score too high?
Liaoning Chengda Biotechnology Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Liaoning Chengda Biotechnology Co's value of 6 is 100% above this industry median. Based on the distribution chart, Liaoning Chengda Biotechnology Co ranks #107 out of 1331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liaoning Chengda Biotechnology Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Liaoning Chengda Biotechnology Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Liaoning Chengda Biotechnology Co ranks #107 out of 1331 companies for Piotroski F-Score. This places Liaoning Chengda Biotechnology Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Liaoning Chengda Biotechnology Co's value of 6 is 100% above this benchmark. Historically, Liaoning Chengda Biotechnology Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Liaoning Chengda Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liaoning Chengda Biotechnology Co's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Liaoning Chengda Biotechnology Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liaoning Chengda Biotechnology Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liaoning Chengda Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co (SHSE:688739) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.14, compared to a current price of ¥19.65 — trading 11.2% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 100% above the Biotechnology industry median of 3.00. Liaoning Chengda Biotechnology Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Liaoning Chengda Biotechnology Co (SHSE:688739), the current Piotroski F-Score is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liaoning Chengda Biotechnology Co (SHSE:688739) Overvalued in 2026?

Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co stock appears to be undervalued. The current stock price of ¥19.65 is trading 11.2% below its estimated GF Value™ of ¥22.14. GuruFocus considers Liaoning Chengda Biotechnology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688739:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: ¥22.14 vs. price of ¥19.65 (11.2% below fair value)
  • GF Score™: 69/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#107 of 1331)

No single metric tells the full story. See the SHSE:688739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Liaoning Chengda Biotechnology Co Business Description

Address No. 1, Xinfang Street, Hunnan New District, Liaoning Province, Shenyang, CHN, 110179
Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.
69GF Score

Get the complete analysis for SHSE:688739

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.65
Price
¥22.14
GF Value